

Avelumab JAVELIN Merkel 200 (Part B - treatment-naïve patients)

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Upgraded based on expanded access and real-world experience



Avelumab JAVELIN Merkel 200 (Part B - treatment-naïve patients)

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Adult patients with metastatic Merkel cell carcinoma (MCC)  
Experimental Arm: Avelumab  
Control Arm: Single arm (Phase II)



